CliniGA CRO

CliniGA CRO Blog

Sharing necessary information safely in governance prereads

A governance preread may reach people with different roles and access permissions.

Representative research photograph: Sharing necessary information safely in governance prereads
Photo: National Center for Advancing Translational Sciences · License: Public domain · Cropped and resized.
Published
Updated

A governance preread may reach people with different roles and access permissions. Greater detail does not always support a better decision. Sponsors should provide necessary information while respecting personal data, commercial confidentiality and the trial's blinding arrangements throughout the preparation and distribution process.

Decision framework

Write the decision question first. Separate information needed for that choice from detail requiring review by particular specialists. Do not automatically copy recipients from an old meeting invitation. For potentially unblinding material, determine appropriate independent review and authorised access routes according to the trial's arrangements.

Worked example

For example, a presentation explaining site delays contains participant names and detailed health information, although the decision concerns additional coordination resources. The team provides an aggregated workload account while necessary medical detail remains with authorised reviewers. Reducing unnecessary information supports purpose-appropriate sharing rather than concealing the underlying problem.

Implementation checks

  • Ask what decision purpose each attachment or table serves and whether its recipients have appropriate access authority.
  • Test link permissions against the actual recipient group instead of routinely using files with broad organisational access.
  • Define how an updated package is distinguished from previous versions and how an accidental misdirection is reported.

Acceptance and boundaries

Accept the package when the board can decide and necessary specialist detail remains available through a suitable channel. Summarisation must not suppress important safety information. Assess confidentiality and blinding against trial plans and appropriate expert processes; this example is not itself a legal authorisation to share data.

Frequently asked questions

Does every board member need all available data?
No. Assess access according to the person's role and the purpose of the decision.
Does sending the preread complete the record?
The decision outcome must also be linked to relevant records and the applicable version retained.

Sources

  1. EMA — ICH E6 good clinical practice
  2. WHO — Guidance for best practices for clinical trials